The Cancer Letter

Inside information on cancer research and drug development

Clinical

OBI-822/821 Phase II/III Study Does Not Meet PFS Endpoint, But Shows Positive Results in Breast Cancer Patients with Immune Response

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

OBI Pharma Inc., announced topline results from a phase II/III study of OBI-822/821 (formerly OPT822/OPT821), which evaluated the clinical benefit and immunogenicity in patients with metastatic breast cancer. The study did not meet the primary efficacy endpoint of progression-free survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice

When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant.  This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I...

By Jacquelyn Cobb

Login

Site license subscribers:
Log in with your IP | Register a sponsored account